On December 12 and 13, 2019 a Working Group and Management Committee meeting was held in Malta for a COST action, bringing together 60 clinicians and researchers to advance MRI diagnostics for glioblastoma.
During this two-day meeting participants created and strengthened collaborations and brainstormedon the objectives of this Action. The program was packed with talks by experts in the field discussingthe technological and clinical aspects of diffusion, perfusion and MRS. Additionally, DSC-MRI and vascular habitats were discussed. Next to these talks, 25 members were invited to present their research projects during the ‘Meet & Greet with the GliMR membership’-sessions, allowing all participants to get to know all aspects within the field and to liaise with each other. To truly spark discussion, two brainstorm sessions were organized. During the first brainstorm session, all participants were invited to discuss both the advantages and disadvantages of several novel MRI-techniques, such as diffusion, perfusion, machine learning, and many other emerging sequences, in a game-like format. During the second brainstorm, issues complicating the set-up of international research projects were discussed, such as data-sharing, knowledge-sharing and GDPR.
The Research team of Konstantinion Research Center of Molecular Medicine and Biotechnology presented innovative studies based on cellular pathways, which activate glioblastoma for the brain and don’t let patient to survive in more than 15 months besides the chemotherapy, radiation therapy, surgery, or immunotherapy with monoclonal antibodies.
The team of Konstantinion Center presented all the scientific pathways for glioblastoma based on targeted monoclonal antibodies (growth factors or cytokines), as they were investigated in the global bibliography.
Konstantinion Research center will be in position to investigate and detect and measure with bioactive compounds (with no side effects) and to block all cancer pathways in order the cancer patients to have prolongation of life and live much better. So, these tests will include testing and evaluating the metabolism, multiplication, epithelial mesenchymal transition (EMT), metastasis, adhesion, and survival of the cancer cells. All these testing will be combined with the classical therapies (chemotherapy, radiation therapy, surgery, or immunotherapy with monoclonal antibodies) for the better management of the Glioblastoma patients.
